Информация, предоставленная GHD в любой форме носит рекомендательный и информативный характер с целью ознакомления с различными методами лечения и вариантами их применения для конкретного пациента. Использование любой информации, опубликованной на данном сайте или предоставленной сотрудниками, консультантами или любым другим лицом от имени GHD, осуществляется исключительно под личную ответственность.

© 2019 by Global Healthcare Direct Limited

Lu Daopei Hospital 

Beijing, China


The story of CAR-T therapy in China is inseparably linked with the Lu Daopei Hospital, named after its founder professor Lu Daopei.

Lu Daopei is an outstanding Chinese scientist, a world-famous unique specialist in bone marrow transplantation. Professor Lu was at the forefront of bone marrow transplantation in China and was the first to conduct such operation in Asia in 1964. It took him years of research and clinical experience to become a world-famous scientist.

The Chinese CAR-T cell method has become attractive because it has produced very good efficacy thus far, combined with relative safety. That China or other sites outside the US can be part of such collaborations may be the new reality and, perhaps, the wave of the future. As one of the most active Immunotherapy centers general hematology department of Lu Daopei Hospital has completed more than 470 cases modified second generation CAR-T clinical trials.

The CAR-T clinical trial in Lu Daopei Hospital is for patients with:

  • B-cell acute lymphoblastic leukemia (B-ALL), 

  • B Cell Lymphoma, 

  • Multiple myeloma (MM), 

  • Acute Myeloid Leukemia (AML),

who developed refractory or relapsed disease from chemotherapy.

CAR-T therapy could help patient into complete remission. CAR-T therapy complete recovery rate is about 90%. And bridging BMT after CAR-T for B-ALL could further increase the potential cure rate.


-Chief scientist, world-famous hematologist and China key discipline leader

-Founder of Institute of Hematology, Peking University

-Distinguished Professor at Peking University, Fudan University and Wuhan University

-Vice Chairman of the 19~22th Chinese Medical Association, former Vice Chairman of Asian Hematology Association (AHA) 

-Awarded as the Academician of Chinese Academy of Engineering in 1996


Daopei Lu


-Medical Executive President of Lu Daopei Hospital 
-Director of Lymphoma and Multiple Myeloma Center

Director of Hematology and Oncology  department

American Board Certified Hematology & Oncology

American medical license of Hematology & Oncology, Chinese medical license

Member of ASH,ASCO & CAHON

The first session of the executive member of CNMIA

The chairman of Specialty Committee of Hematology of  CNMIA

Hematologist, Clinical Professor

Peihua (Peggy) Lu, M.D.

The president Lu Daopei Hospital, Peihua (Peggy) Lu, is one of the most renowned experts in CAR-T therapy. A doctor with a brilliant education who worked at Stanford University (USA) for many years, Dr. Lu conducts a series of studies aimed at expanding the list of diagnoses for which this type of therapy can be used.

The research laboratory is located on the territory of hospital, that helps specialists quickly modify existing treatment protocols individually for each patient. The hospital's specialists were able to improve the technology by combining CAR-T with allogeneic hematopoietic transplantation, which significantly reduces the risk of relapse and further improves the prognosis.

Lu Daopei Hospital is specialized in leukemia, myeloma, lymphomas and malignant anemia and achieves quick results. Blood cancers are the only indication for the use of CAR-T therapy.

Modified second generation CAR-T therapy in our hospital. Completed more than 500 cases:
  • Less CAR-T cells infusion can reduce the cost and side effects severity but a threshold dosage for CAR-T cell infusion is required to in vivo expansion and therapeutic efficacy. 
  • The side effects severity is related to the leukemia burden and the numbers of infused CAR-T cells. 
  • CAR-T cell transduction efficiency and viability are negatively related to the leukemia burden in bone marrow. 
  • CD19 negative relapse has been observed.
  • Resulted in high complete remission/incomplete count recovery rate (92 pts with 90% complete remission/incomplete count recovery, 100% in most recent 40 cases).
  • The response can be achieved with less CAR-T cells ( 1×105/kg).
  • Bridge to allo-Hematopoietic Transplantation may improve the cure rate (84% CCR upto now by allo-HSCT after CAR-T with median observation 200 days)